1. Bristol-Myers Squibb is Buying Celgene in a $74 Billion Deal

    Bristol-Myers Squibb is Buying Celgene in a $74 Billion Deal
    • Bristol-Myers Squibb has agreed to acquire Celgene, the drugmakers announced Thursday in a deal valued at $74 billion.
    • The deal will pay Celgene shareholders one BMS share and $50 cash for each Celgene share they own.
    • The deal combines a massive pharmaceutical company with a biotech giant, both of which have a big presence in cancer drug development...
    Read Full Article

    Login to comment.

  1. Categories

    1. BoardProspects Features:

      BoardBlogs, BoardKnowledge, BoardMoves, BoardNews, BoardProspects Announcements, BoardProspects CEO, CEO Blog, In the News, Partner Publications, Question of The Week, Sponsored Content
  2. Quotes

    1. As a combined entity, we will enhance our leadership positions across our portfolio, including in cancer and immunology and inflammation.
  3. Topics Mentioned

  4. Authors